$HOOK News
Last published 7mo ago
- 7mo agoHOOKHOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail TherapeuticsGlobeNewswireNEW YORK and VIENNA, March 26, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA", the "Company") today announced the completion of the sale of its immuno-oncology related assets, consisting primarily
- 9mo agoHOOKHOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail TherapeuticsGlobeNewswireNEW YORK and VIENNA, Austria, Feb. 03, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA", the "Company") today announced the sale of its immuno-oncology related assets, consisting primarily of the
- 1y agoHOOKHOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to GileadGlobeNewswireNEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA") today announced the completion of the sale of its assets related to HOOKIPA's HB-400 program and certain of its assets
- 1y agoHOOKHOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common StockGlobeNewswireNEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA")), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer
- 1y agoHOOKHOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIVGlobeNewswireHB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HIV) Under the
- 1y agoHOOKHOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure RequirementsGlobeNewswireNEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for
- 1y agoHOOKHOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business UpdatesGlobeNewswireEnrollment of 68 patients completed Phase 2 study for eseba-vec + pembrolizumab in HPV+ HNSCC four months ahead of schedule SITC 2024 late-breaking poster highlights Phase 2 eseba-vec data updates for increased
- 2y agoHOOKHOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-BreakerGlobeNewswireNEW YORK and VIENNA, Nov. 11, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the
- 2y agoHOOKHOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024GlobeNewswireNEW YORK and VIENNA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the
- 2y agoHOOKHOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck CancerGlobeNewswireStudy done in collaboration with Memorial Sloan Kettering and led by Dr. Winston Wong, Head and Neck Oncologist and Dr. Alan Ho, Chief of the Head and Neck Oncology Service IIT will evaluate eseba-vec in patients who
- 2y agoHOOKHOOKIPA Pharma to Present Strong Preclinical HB-700 DatasetGlobeNewswireNEW YORK and VIENNA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a clinical-stage biopharmaceutical company developing next generation immunotherapeutics for the
- 2y agoHOOKHOOKIPA Pharma Announces Board of Directors ChangesGlobeNewswireNEW YORK and VIENNA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK) ("HOOKIPA" or the "Company"), a company developing a new class of immunotherapeutics based on its proprietary arenavirus
- 2y agoHOOKHOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewswireNEW YORK and VIENNA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA", the "Company")), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform,
- 2y agoHOOKHOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswireNew Leadership Appointments; Positive Clinical and Regulatory Reports for the Lead Product Candidate, HB-200 (eseba-vec); On track to initiate the Phase 2/3 "AVALON-1" study with eseba-vec in Q4 2024 ASCO 2024
- 2y agoARVNGMDAHOOKHOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200GlobeNewswireDirector Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial OfficerCompany is conducting a review of its business operations and strategy to
- 2y agoHOOKHOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock SplitGlobeNewswireNEW YORK and VIENNA, July 08, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, "HOOKIPA")), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced
- 2y agoHOOKHOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIVGlobeNewswireNovel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (Gilead), to be evaluated as a potential component of a curative regimen for human immunodeficiency virus (HIV)HOOKIPA achieves
- 2y agoHOOKHOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual MeetingGlobeNewswireEncouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated with HB-200 plus pembrolizumabIn a subset of 17 evaluable patients with PD-L1 combined positive
- 2y agoHOOKHOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual MeetingGlobeNewswireCompany will present promising preliminary progression-free survival and overall survival data for patients with combined positive score (CPS) ≥20Conference call on Tuesday, June 4, at 4:15 p.m. ET NEW YORK and VIENNA,
- 2y agoHOOKHOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual MeetingGlobeNewswireHOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile and promising
- 2y agoHOOKHOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswirePhase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligns with U.S. Food and Drug Administration
- 2y agoHOOKHOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with PembrolizumabGlobeNewswirePhase 2/3 pivotal trial design and protocol for HB-200 in combination with pembrolizumab for the first-line treatment of patients with HPV16+ recurrent or metastatic OPSCC aligned with FDA feedback HB-200 accepted for
- 2y agoHOOKHOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated CancersGlobeNewswireNEW YORK and VIENNA, Austria, April 24, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
- 2y agoHOOKHOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW YORK and VIENNA, Austria, April 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
- 2y agoHOOKHOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to RegistrationGlobeNewswireHOOKIPA announces alignment with FDA on pivotal trial design and protocol for HB-200 in combination with pembrolizumabHB-200 program receives Priority Medicines (PRIME) designation from EMA NEW YORK and VIENNA, Austria,
- 2y agoHOOKHOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsGlobeNewswireBest-in-class preliminary Phase 2 data for HB-200 in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancers in the first line setting Expect updated Phase 2 data with
- 2y agoHOOKHOOKIPA Pharma to Participate in Leerink Partners Global Biopharma ConferenceGlobeNewswireNEW YORK and VIENNA, Austria, March 06, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
- 2y agoHOOKHOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership ProgramsGlobeNewswireHOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease HOOKIPA will regain global development rights to HB-700 program
- 2y agoHOOKHOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development OrganizationGlobeNewswireNEW YORK and VIENNA, Austria, Jan. 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
- 2y agoHOOKHOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead SciencesGlobeNewswireGilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per shareFollowing the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA's outstanding shares of common
- 2y agoHOOKHOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency VirusGlobeNewswireNovel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (‘Gilead'), to be evaluated as a potential curative regimen for human immunodeficiency virus (HIV)Phase 1 trial to commence in
- 3y agoHOOKHOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewswireReported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer; data reinforce strong objective response
- 3y agoHOOKHOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023GlobeNewswireHB-200 monotherapy induced a robust increase in circulating tumor-specific CD8+ T cells in all evaluable Phase 1 patients with heavily pretreated HPV16+ head and neck cancer T cell responses were high quality, durable
- 3y agoHOOKHOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023GlobeNewswireNEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
- 3y agoHOOKHOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023GlobeNewswire42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line setting—doubling historical ORR reported with pembrolizumab alone1
- 3y agoHOOKHOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead SciencesGlobeNewswireHB-400, a novel arenaviral therapeutic vaccine, generates robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical settingA Gilead-led Phase 1 clinical trial to evaluate the safety
- 3y agoHOOKHOOKIPA Announces Executive Leadership ChangeGlobeNewswireNEW YORK and VIENNA, Sept. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
- 3y agoHOOKHOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW YORK and VIENNA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
- 3y agoHOOKHOOKIPA Pharma to participate in upcoming investor conferences in SeptemberGlobeNewswireNEW YORK and VIENNA, Austria, Sept. 06, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
- 3y agoANEBDLHCHBIOHOOK+15Sidoti Events, LLC's Virtual August Micro-Cap ConferenceACCESS NewswireNEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place
- 3y agoHOOKHOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewswireHOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line setting for advanced head and neck cancerRecruitment ongoing for two Phase 1 clinical trials (HB-300 for advanced
- 3y agoHOOKHOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023GlobeNewswireNEW YORK and VIENNA, Austria, Aug. 03, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
- 3y agoHOOKHOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireNEW YORK and VIENNA, Austria, June 10, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
- 3y agoHOOKHOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred StockGlobeNewswireNEW YORK and VIENNA, Austria, May 31, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
- 3y agoHOOKHOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck CancersGlobeNewswireHB-200 in combination with pembrolizumab doubled the objective response rate of 1st-line pembrolizumab for patients with recurrent/metastatic head and neck cancer HOOKIPA is preparing to start a pivotal trial of
- 3y agoFWBIGMDAHOOKGamida Cell Appoints Terry Coelho as CFOBusiness WireIndustry veteran Coelho brings more than 35 years of experience at emerging growth and global companies to role; Shai Lankry to leave company June 2 Gamida Cell Ltd. (NASDAQ:GMDA), a cell therapy pioneer working to
- 3y agoHOOKHOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewswireHOOKIPA on track to report Phase 2 data on HB-200 for head and neck cancer in combination with pembrolizumab in 2Q 2023Phase 1 clinical trials initiated for two programs (HB-300 for advanced prostate cancer and
- 3y agoHOOKHOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis BGlobeNewswireNEW YORK and VIENNA, Austria, May 09, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
- 3y agoHOOKHOOKIPA Pharma to Participate in Upcoming Investor Conferences in MayGlobeNewswireNEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today
- 3y agoHOOKHOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023GlobeNewswireNEW YORK and VIENNA, Austria, May 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ:HOOK, ‘HOOKIPA')), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today